BLUEJET Blue Jet Healthcare Q2 FY25 results (Jul–Sep 2024) and concall
Blue Jet Healthcare reported a strong Q2 FY25, achieving its highest ever quarterly PAT of ₹58.3 crores, driven by a 28% sequential and 18% YoY increase in turnover to ₹207.1 crores. The company successfully commissioned Plant 6, adding 120 KL capacity for PI and contrast media, and initiated commercial production for a key cardiovascular therapy client. Despite ongoing Red Sea issues impacting goods in transit, management expressed confidence in demand across all segments and outlined plans for further capacity expansion and R&D augmentation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 |
|---|---|
| Revenue | 208 |
| EBITDA | 69 |
| Net profit | 58 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
